Acupuncture And Mucosal Immunity In The Upper Respiratory Tract
Funder
National Health and Medical Research Council
Funding Amount
$383,082.00
Summary
Many Australians seek complementary and alternate medicine for the treatment of allergic diseases such as allergic rhinitis. There is evidence that acupuncture treatment is clinically beneficial for the treatment of allergic rhinitis. This project will produce new information that will provide a scientific basis of how acupuncture influences the immune response and modulates inflammation. Broader application to other inflammatory diseases and therapeutic interventions is possible.
Understanding The Role Of MAIT Cells In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$547,593.00
Summary
A specialised set of T lymphocytes called Mucosal Associated Invariant T (MAIT) cells protect us from bacteria and yeast at mucosal sites where the body's immune defences are most easily breached, e.g. gut, oral cavity, airways & reproductive tract. This study investigates the role of MAIT cells in health and in diseases like inflammatory bowel disease, peptic ulceration, periodontitis and tuberculosis. Controlling MAIT cells could help in treating these conditions.
This research deals with the interaction between the reproductive system and the immune system, providing a unique perspective on two biological systems that are normally considered separately. This research may help to improve the treatment of infertility, reproductive tract infections and testicular cancer, but may also lead to new treatments for inflammatory diseases that hospitalise or kill many thousands of patients each year, and for preventing graft failure in transplant recipients.
Sytemic And Mucosal Functional Antibodies In Protection Against HIV
Funder
National Health and Medical Research Council
Funding Amount
$559,501.00
Summary
Only one human HIV vaccine has shown any level of protective efficacy. However the mechanisms behind how this vaccine was protective are still not fully understood. Additionally, HIV is primarily transmitted through mucosal sites, however very little is know about vaccine immune responses at these sites. Thus this proposal aims to further define the mechanisms of antibody protection against HIV at both systemic and mucosal locations, in order to guide future HIV vaccine design efforts.
A Multi-protein Vaccine Targeting The Oral Pathogens Associated With Chronic Periodontitis
Funder
National Health and Medical Research Council
Funding Amount
$717,692.00
Summary
Periodontitis is a chronic inflammatory disease associated with specific bacteria leading to the destruction of the toothÍs supporting tissues and ultimately tooth loss and is a major public health problem in all societies. Our research is focused on designing a vaccine that targets the major bacteria associated with periodontitis. We aim to produce a triple antigen vaccine and investigate the applicability of a vaccine administered under the tongue as an alternative to needle injections.
PH-dependent, Antibody-mediated Enhancement Of Genital Chlamydial Infection: Implications For Vaccine Design ?
Funder
National Health and Medical Research Council
Funding Amount
$373,228.00
Summary
Antibody found in cervicovaginal secretions is predominantly of the IgG subclass. In the acidic environment of the female reproductive tract IgG antibodies against surface antigens on Chlamydia may actually enhance rather than prevent infection, due to uptake of IgG-coated bacteria by the neonatal Fc receptor (FcRn), which is found on the surface of epithelial cells in the reproductive tract. The proposed studies will determine the effects of chlamydial antibodies on the course of infection.
Prevention Of Asthma In Young Children Via Immunostimulation
Funder
National Health and Medical Research Council
Funding Amount
$679,683.00
Summary
Persistent asthma is a major problem for Australia yet none of the current therapies do more that control the condition. The long-term solution is to prevent asthma from progressing to the persistent form. The major risk factors are: family history, early allergy and recurrent severe lower respiratory infections (sLRI) in the early life. We will conduct a randomized clinical trial to prevent sLRI using a novel bacterial-derived immunostimulant in infants at high risk of developing asthma.